309 related articles for article (PubMed ID: 18018761)
1. Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study.
Rumi MG; Aghemo A; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
Antivir Ther; 2007; 12(7):1033-40. PubMed ID: 18018761
[TBL] [Abstract][Full Text] [Related]
2. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
3. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
Aghemo A; Rumi MG; Soffredini R; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
Antivir Ther; 2006; 11(6):797-802. PubMed ID: 17310824
[TBL] [Abstract][Full Text] [Related]
4. The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype.
Aghemo A; Rumi MG; Monico S; Prati GM; D'Ambrosio R; Donato MF; Colombo M
Antivir Ther; 2009; 14(4):577-84. PubMed ID: 19578243
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.
Roffi L; Colloredo G; Pioltelli P; Bellati G; Pozzpi M; Parravicini P; Bellia V; Del Poggio P; Fornaciari G; Ceriani R; Ramella G; Corradi C; Rossini A; Bruno S;
Antivir Ther; 2008; 13(5):663-73. PubMed ID: 18771050
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
7. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension.
Giannini EG; Basso M; Savarino V; Picciotto A
J Intern Med; 2009 Dec; 266(6):537-46. PubMed ID: 19849774
[TBL] [Abstract][Full Text] [Related]
9. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
10. The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1.
Bárcena R; Moreno A; del Campo S; Muriel A; Mateos ML; Garrido E; García M; Quereda C; Moreno S; Moreno A
Antivir Ther; 2007; 12(3):401-6. PubMed ID: 17591030
[TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
[TBL] [Abstract][Full Text] [Related]
12. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.
Payan C; Pivert A; Morand P; Fafi-Kremer S; Carrat F; Pol S; Cacoub P; Perronne C; Lunel F;
Gut; 2007 Aug; 56(8):1111-6. PubMed ID: 17363475
[TBL] [Abstract][Full Text] [Related]
13. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C.
Núnez M; Camino N; Ramos B; Berdún MA; Barreiro P; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Martín-Carbonero L; Romero M; García-Samaniego J; Soriano V
Antivir Ther; 2005; 10(5):657-62. PubMed ID: 16152759
[TBL] [Abstract][Full Text] [Related]
14. An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.
Andriulli A; Nardi A; Di Marco V; Ippolito AM; Gavrila C; Aghemo A; Di Paolo D; Squadrito G; Grassi E; Calvaruso V; Valvano MR; Brancaccio G; Craxi A; Angelico M;
Dig Liver Dis; 2014 Sep; 46(9):818-25. PubMed ID: 24953209
[TBL] [Abstract][Full Text] [Related]
15. Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.
Todorovska B; Joksimovic N; Caloska-Ivanova V; Dimitrova-Genadieva M; Trajkovska M; Curakova E; Kiprijanovska S; Zafirova-Ivanovska B; Serafimoski V
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Mar; 38(1):25-33. PubMed ID: 28593897
[TBL] [Abstract][Full Text] [Related]
16. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
17. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.
Di Marco V; Almasio PL; Ferraro D; Calvaruso V; Alaimo G; Peralta S; Di Stefano R; Craxì A
J Hepatol; 2007 Oct; 47(4):484-91. PubMed ID: 17692985
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
19. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.
Sjogren MH; Sjogren R; Holtzmuller K; Winston B; Butterfield B; Drake S; Watts A; Howard R; Smith M
Dig Dis Sci; 2005 Apr; 50(4):727-32. PubMed ID: 15844709
[TBL] [Abstract][Full Text] [Related]
20. Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients.
Roomer R; Bergmann JF; Boonstra A; Hansen BE; Haagmans BL; Kwadijk-de Gijsel S; van Vuuren AJ; de Knegt RJ; Janssen HL
Antivir Ther; 2012; 17(3):509-17. PubMed ID: 22300892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]